主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PRTC
#5776
PureTech Health plc American Depositary Shares
16.7
7
+0.72%
版块:
基础:
利润货币:
日范围
年范围
日变化
+0.72%
每月变动
-11.69%
6个月变化
-4.17%
年变化
-5.79%
前一天收盘价
16.6
5
Open
17.0
0
Bid
Ask
Low
16.7
7
High
17.0
0
交易量
2
市场
股票
医疗保健
PRTC
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
285.89 M
287.8 M
278.57 M
271.85 M
239.42 M
1.08 B
Valuation ratios
Enterprise value
15.76 B
10.19 B
—
6.61 B
4.15 B
—
Price to earnings ratio
—
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
—
Price to book ratio
—
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0
0.07
0.05
0.1
0.05
—
Return on equity %
0.01
0.11
0.07
0.15
0.07
—
Return on invested capital %
—
—
—
—
—
—
Gross margin %
100
100
100
100
100
—
Operating margin %
1 015.73
864.29
1 266.53
4 390.36
2 818.87
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
38.82
360.65
237.32
2 000.84
575.43
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
2.29
2.22
3.99
6.76
9.33
—
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.01
0.02
0.02
0
0.01
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
—
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
—
Working capital per share
—
—
—
—
—
—
Book value per share
—
—
—
—
—
—
PureTech Health plc - American Depositary Shares
PureTech Health is an American biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange.
新闻
Deupirfenidone获得罕见肺病孤儿药资格
Deupirfenidone receives orphan drug status for rare lung disease
PureTech的deupirfenidone获得FDA和欧盟治疗特发性肺纤维化孤儿药资格
PureTech’s deupirfenidone receives FDA and EU orphan drug status for IPF
PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PureTech CEO to present at J.P. Morgan Healthcare Conference
PureTech Health任命Robert Lyne为永久首席执行官
PureTech Health appoints Robert Lyne as permanent CEO
PureTech在股东担忧后提供股东大会结果更新
PureTech provides update on AGM results following shareholder concerns
PureTech股价在FDA关于IPF药物会议后下跌
PureTech stock falls after FDA meeting on IPF drug